The Department of Health and Social Care (DHSC) has increased the NHS reimbursement prices for all strengths of Mounjaro dispensed from September to reflect the new, higher list prices.
The move follows after the Community Pharmacy England (CPE) reached an agreement with DHSC that reimbursement of NHS prescriptions for Mounjaro dispensed from September will be reimbursed at the increased UK list prices. This will help pharmacy owners avoid selling Mounjaro at a loss.
The new Mounjaro reimbursement prices from September are as follows: Tripeptide 2.5mg (£133), Tirzepatide 5mg (£180), Tirzepatide 7.5mg (£255), Tirzepatide 10mg (£255), Tirzepatide 12.5mg (£330), and Tirzepatide 15mg (£330).
The redetermined reimbursement prices will apply to September prescriptions.
Community Pharmacy clarified that its remit is restricted to NHS pharmacy services and we are therefore unable to address queries relating to the private supply of Mounjaro.
National Pharmacy Association chair, Olivier Picard, said, "Pharmacies are working hard to support their patients and explore if there are options to minimise disruption to their treatment programme."
Eli Lilly had earlier announced that it will increase the NHS list prices of all strengths of its Mounjaro (tirzepatide) KwikPen from 1 September.
